Systematische Übersicht
Treatment Discontinuation, Interruption, and Rechallenge With Enfortumab Vedotin Plus Pembrolizumab in a Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review
Cureus · 19.11.2026
DOI: 10.7759/cureus.119928 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cureus, erschienen am 19.11.2026. Verfasst von Misbah Kassam und 1 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kassam, M., & Sharif, F. (2026). Treatment Discontinuation, Interruption, and Rechallenge With Enfortumab Vedotin Plus Pembrolizumab in a Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.119928
Vancouver
Kassam M, Sharif F. Treatment Discontinuation, Interruption, and Rechallenge With Enfortumab Vedotin Plus Pembrolizumab in a Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review. Cureus. 2026. doi:10.7759/cureus.119928
BibTeX
@article{Kassam2026,
author = {Kassam, Misbah and Sharif, Faraz},
title = {Treatment Discontinuation, Interruption, and Rechallenge With Enfortumab Vedotin Plus Pembrolizumab in a Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.119928}
}
EUVIMED